Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Enamptcumab by Aqualung Therapeutics for Lung Injury: Likelihood of Approval
Enamptcumab is under clinical development by Aqualung Therapeutics and currently in Phase II for Lung Injury. According to GlobalData, Phase...
Data Insights
Enamptcumab by Aqualung Therapeutics for Acute Respiratory Distress Syndrome: Likelihood of Approval
Enamptcumab is under clinical development by Aqualung Therapeutics and currently in Phase II for Acute Respiratory Distress Syndrome. According to...